Inhibikase Therapeutics (IKT) Competitors

$1.86 -0.04 (-2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 0.00 (0.00%)

As of 04:10 PM Eastern

IKT vs. SEPN, SVRA, CVAC, AKTS, and ALVO

Should you buy Inhibikase Therapeutics stock or one of its competitors? MarketBeat compares Inhibikase Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibikase Therapeutics include Septerna (SEPN), Savara (SVRA), CureVac (CVAC), Aktis Oncology (AKTS), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does Inhibikase Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Septerna had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 7 mentions for Septerna and 5 mentions for Inhibikase Therapeutics. Septerna's average media sentiment score of 0.48 beat Inhibikase Therapeutics' score of 0.38 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Inhibikase Therapeutics has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	27.78	-$48.88M	-$1.11	N/A
Inhibikase Therapeutics	$260K	944.74	-$48.26M	-$0.48	N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Septerna currently has a consensus price target of $43.13, indicating a potential upside of 52.28%. Inhibikase Therapeutics has a consensus price target of $5.50, indicating a potential upside of 195.70%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

Inhibikase Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Inhibikase Therapeutics	N/A	-46.92%	-43.72%

Septerna has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

Inhibikase Therapeutics beats Septerna on 10 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Inhibikase Therapeutics' return on equity of -46.92% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-92.93%	-69.60%
Inhibikase Therapeutics	N/A	-46.92%	-43.72%

Savara currently has a consensus price target of $9.13, indicating a potential upside of 73.15%. Inhibikase Therapeutics has a consensus price target of $5.50, indicating a potential upside of 195.70%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

In the previous week, Savara had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Savara and 5 mentions for Inhibikase Therapeutics. Savara's average media sentiment score of 0.60 beat Inhibikase Therapeutics' score of 0.38 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

87.9% of Savara shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Savara has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Inhibikase Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Inhibikase Therapeutics	$260K	944.74	-$48.26M	-$0.48	N/A

Summary

Inhibikase Therapeutics beats Savara on 11 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to CureVac?

Inhibikase Therapeutics (NASDAQ:IKT) and CureVac (NASDAQ:CVAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CureVac has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	944.74	-$48.26M	-$0.48	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Inhibikase Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-46.92%	-43.72%
CureVac	199.92%	-23.03%	-19.09%

Inhibikase Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Inhibikase Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 195.70%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 46.64%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Inhibikase Therapeutics and 0 mentions for CureVac. Inhibikase Therapeutics' average media sentiment score of 0.38 beat CureVac's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
CureVac	Neutral

Summary

CureVac beats Inhibikase Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Aktis Oncology's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	-46.92%	-43.72%

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aktis Oncology currently has a consensus price target of $32.00, suggesting a potential upside of 64.10%. Inhibikase Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 195.70%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

In the previous week, Aktis Oncology had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 7 mentions for Aktis Oncology and 5 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.38 beat Aktis Oncology's score of -0.16 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aktis Oncology has higher revenue and earnings than Inhibikase Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	160.20	N/A	N/A	N/A
Inhibikase Therapeutics	$260K	944.74	-$48.26M	-$0.48	N/A

Summary

Aktis Oncology and Inhibikase Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Inhibikase Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
Inhibikase Therapeutics	N/A	-46.92%	-43.72%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 121.57%. Inhibikase Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 195.70%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

In the previous week, Alvotech had 4 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 9 mentions for Alvotech and 5 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.38 beat Alvotech's score of 0.27 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alvotech has higher revenue and earnings than Inhibikase Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.76	$27.92M	-$0.25	N/A
Inhibikase Therapeutics	$260K	944.74	-$48.26M	-$0.48	N/A

Alvotech has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Summary

Inhibikase Therapeutics beats Alvotech on 10 of the 16 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$245.63M	$466.61M	$4.27B	$12.46B
Dividend Yield	N/A	N/A	6.10%	5.30%
P/E Ratio	-4.33	N/A	22.80	25.58
Price / Sales	944.74	357.46	181.55	63.56
Price / Cash	N/A	N/A	51.43	55.34
Price / Book	0.81	3.16	36.91	6.70
Net Income	-$48.26M	-$81.71M	$114.78M	$333.77M
7 Day Performance	-6.53%	3.98%	4.22%	0.45%
1 Month Performance	9.41%	4.77%	5.56%	4.06%
1 Year Performance	N/A	N/A	16.37%	36.21%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	2.3732 of 5 stars	$1.86 -2.1%	$5.50 +195.7%	N/A	$245.63M	$260K	N/A	6	News Coverage Earnings Report
SEPN Septerna	3.4107 of 5 stars	$23.57 -1.3%	$43.13 +83.0%	+267.8%	$1.07B	$45.95M	N/A	N/A	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
SVRA Savara	2.5288 of 5 stars	$5.12 -2.1%	$9.13 +78.2%	+77.4%	$1.07B	N/A	N/A	20	Positive News Earnings Report
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
AKTS Aktis Oncology	1.6913 of 5 stars	$18.27 -1.8%	$32.00 +75.2%	N/A	$993.30M	$6.50M	N/A	76	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. SEPN, SVRA, CVAC, AKTS, and ALVO

How does Inhibikase Therapeutics compare to Septerna?

Summary

How does Inhibikase Therapeutics compare to Savara?

Summary

How does Inhibikase Therapeutics compare to CureVac?

Summary

How does Inhibikase Therapeutics compare to Aktis Oncology?

Summary

How does Inhibikase Therapeutics compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. SEPN, SVRA, CVAC, AKTS, and ALVO

How does Inhibikase Therapeutics compare to Septerna?

Does the media refer more to SEPN or IKT?

Which has stronger valuation and earnings, SEPN or IKT?

Do institutionals and insiders believe in SEPN or IKT?

Do analysts rate SEPN or IKT?

Is SEPN or IKT more profitable?

Which has more volatility and risk, SEPN or IKT?

Summary

How does Inhibikase Therapeutics compare to Savara?

Is SVRA or IKT more profitable?

Do analysts rate SVRA or IKT?

Does the media refer more to SVRA or IKT?

Do institutionals and insiders believe in SVRA or IKT?

Which has more volatility and risk, SVRA or IKT?

Which has stronger valuation and earnings, SVRA or IKT?

Summary

How does Inhibikase Therapeutics compare to CureVac?

Do institutionals & insiders have more ownership in IKT or CVAC?

Which has better earnings and valuation, IKT or CVAC?

Is IKT or CVAC more profitable?

Which has more risk and volatility, IKT or CVAC?

Do analysts prefer IKT or CVAC?

Does the media favor IKT or CVAC?

Summary

How does Inhibikase Therapeutics compare to Aktis Oncology?

Is AKTS or IKT more profitable?

Do institutionals and insiders have more ownership in AKTS or IKT?

Do analysts recommend AKTS or IKT?

Does the media prefer AKTS or IKT?

Which has stronger earnings and valuation, AKTS or IKT?

Summary

How does Inhibikase Therapeutics compare to Alvotech?

Is ALVO or IKT more profitable?

Do institutionals and insiders have more ownership in ALVO or IKT?

Do analysts recommend ALVO or IKT?

Does the media refer more to ALVO or IKT?

Which has stronger earnings and valuation, ALVO or IKT?

Which has more volatility and risk, ALVO or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools